Tag Archives: Joseph Pantginis

BioTime (BTX) Received its Third Buy in a Row

After Maxim Group and Oppenheimer gave BioTime (NYSE MKT: BTX) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Joseph Pantginis reiterated a Buy rating on BioTime today and set a price target

H.C. Wainwright Thinks Ligand Pharma’s Stock is Going to Recover

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharma (LGND – Research Report) today and set a price target of $254. The company’s shares closed yesterday at $113.35, close to its 52-week low of $98.56. Pantginis noted:

Avid Bioservices Inc (CDMO) Receives a Buy from H.C. Wainwright

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Avid Bioservices Inc (CDMO – Research Report), with a price target of $11. The company’s shares closed yesterday at $4.12. Pantginis wrote: “Valuation and impediments

H.C. Wainwright Keeps Their Buy Rating on Rexahn Pharma (RNN)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Rexahn Pharma (RNN – Research Report), with a price target of $10. The company’s shares opened today at $0.56, close to its 52-week low of

H.C. Wainwright Reiterates a Buy Rating on Ligand Pharma (LGND)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Ligand Pharma (LGND – Research Report), with a price target of $254. The company’s shares closed yesterday at $120.61, close to its 52-week low of

Analysts Offer Insights on Healthcare Companies: Beyondspring Inc (NASDAQ: BYSI), Immunomedics (NASDAQ: IMMU) and Nightstar Therapeutics Limited (NASDAQ: NITE)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Beyondspring Inc (BYSI – Research Report), Immunomedics (IMMU – Research Report) and Nightstar Therapeutics Limited (NITE – Research Report). Beyondspring Inc (BYSI) In